BenzingaOctober 26, 2026 at 9:32 AM NYYesterday
Merck Endometrial Cancer Studies Show Significant Survival Gains
Merck reports positive Phase 3 data for Keytruda and sac-TMT in endometrial cancer, showing significant survival gains at ESMO 2026.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
